IP Library Patent Application 13217336
Patent Application
App. No. 13/217,336

Composition and Method for Promoting Wound Healing

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/217,336
Abstract

A composition for promoting wound healing comprises a bioadhesive polymer and a pharmaceutically acceptable liquid medium. Such a composition is applied to a wound to promote healing of the wound. The bioadhesive polymer can be selected from the group consisting of natural or synthetic hydrophilic polymers and hydrogels.

Claims (20)

1 . A composition comprising a bioadhesive polymer and a pharmaceutically acceptable vehicle, wherein the bioadhesive polymer comprises a mucoadhesive adhesive, and the pharmaceutically acceptable vehicle comprises a liquid medium, wherein the composition promotes healing of a wound.

2 . The composition of any one of previous claims, wherein the liquid medium comprises an aqueous medium.

3 . The composition of any one of previous claims, wherein the bioadhesive polymer is suspended or dissolved in the aqueous medium, and wherein the bioadhesive polymer is selected from the group consisting of hydrophilic polymers, hydrogels, and mixtures thereof.

4 . The composition of any one of previous claims, wherein the bioadhesive polymer is selected from the group consisting of polyvinylpyrrolidone, methyl cellulose, carboxymethyl cellulose and its salts, hydroxypropylmethyl cellulose, other hydrophilic cellulose derivatives, alginate and its salts, hyaluronic acid and its salts, and chitosan and derivatives thereof.

5 . The composition of any one of previous claims, wherein the amount of the bioadhesive polymer is in the range from about 0.001 to about 10 percent by weight of the total composition.

6 . The composition of any one of previous claims, wherein the bioadhesive polymer is suspended or dissolved in the aqueous medium; and the bioadhesive polymer comprises a lightly crosslinked poly(acrylic acid) in an amount in the range from about 0.1 to about 7 percent by weight of the total composition.

7 . The composition of any one of previous claims, wherein the crosslinked poly(acrylic acid) is selected from the group consisting of polycarbophil (poly(acrylic acid) crosslinked with divinyl glycol), Carpobol® polymers (poly(acrylic acid) crosslinked with allyl ethers of pentaerythritol or allyl ethers of sucrose), and poly(C 10-30 alkyl acrylate/acrylic acid) crosspolymers.

8 . The composition of any one of previous claims, wherein the composition as disclosed herein has a viscosity in the range from about 2 to about 2,000 centipoises (or mPa·s), as measured by a Brookfield viscometer (Model RVDV Ill) at 25° C. and a shear rate of 1-7 sec −1 , with a CPE-40 spindle.

9 . The composition of any one of previous claims; wherein the bioadhesive polymer comprises a polycarbophil in an amount in the range from about 0.1 to about 7 percent by weight of the total composition; the composition has a viscosity in the range from about 3 to about 1500 mPa·s.

10 . The composition of any one of previous claims, wherein the composition comprises: (a) a bioadhesive polymer; (b) a non-ionic or ionic tonicity agent; (c) a pharmaceutically acceptable preservative; and (d) a pharmaceutically acceptable aqueous medium; wherein the bioadhesive polymer is suspended or dissolved in the aqueous medium; and the bioadhesive polymer comprises a polycarbophil in an amount in the range from about 0.1 to about 7 percent by weight of the total composition; wherein the composition has a viscosity in the range from about 3 to about 1500 mPa·s.

11 . The composition of any one of previous claims, wherein the composition comprises: (a) a bioadhesive polymer; (b) a tonicity agent (non ionic or inonic); (c) a pharmaceutically acceptable preservative; (d) a preservative-enhancing material; and (e) a pharmaceutically acceptable aqueous medium; wherein the bioadhesive polymer is suspended or dissolved in the aqueous medium; and the bioadhesive polymer comprises a polycarbophil in an amount in the range from about 0.1 to about 7 percent by weight of the total composition; wherein the composition has a viscosity in the range from about 3 to about 1500 mPa·s; wherein the preservative-enhancing material is selected from the group consisting of D-glucose, sucrose, maltose, D-mannose, trehalose, glutamic acid, mixtures thereof, and combinations thereof.

12 . The composition of any one of previous claims, wherein the composition comprises: (a) a bioadhesive polymer; (b) a non ionic or inonic tonicity agent; (c) a pharmaceutically acceptable preservative; (d) a preservative-enhancing material; (e) a chelating agent; and (f) a pharmaceutically acceptable aqueous medium; wherein the bioadhesive polymer is suspended or dissolved in the aqueous medium; and the bioadhesive polymer comprises a polycarbophil in an amount in the range from about 0.1 to about 7 percent by weight of the total composition; wherein the composition has a viscosity in the range from about 3 to about 1500 mPa·s, as measured at the condition disclosed herein; wherein the preservative-enhancing material is selected from the group consisting of D-glucose, sucrose, maltose, D-mannose, trehalose, glutamic acid, mixtures thereof, and combinations thereof.

13 . The composition of any one of previous claims, wherein the composition comprises: (a) a bioadhesive polymer; (b) a non ionic or inonic tonicity agent; (c) a pharmaceutically acceptable preservative; (d) a preservative-enhancing material; (e) a chelating agent; and (f) a pharmaceutically acceptable aqueous medium; wherein the bioadhesive polymer is suspended or dissolved in the aqueous medium; and the bioadhesive polymer comprises chitosan or a derivative thereof, in an amount in the range from about 0.1 to about 7 percent by weight of the total composition; wherein the composition has a viscosity in the range from about 3 to about 1500 mPa·s, as measured at the condition disclosed herein; wherein the preservative-enhancing material is selected from the group consisting of D-glucose, sucrose, maltose, D-mannose, trehalose, glutamic acid, mixtures thereof, and combinations thereof.

14 . The composition of any one of the previous claims, further comprising an active pharmaceutical ingredient (or therapeutic agent) selected from the group consisting of anti-inflammatory agents, antibiotics, immunosuppressive agents, antiviral agents, antifungal agents, antiprotozoal agents, combinations thereof, or mixtures thereof.

15 . A method of for promoting wound healing, the method comprising applying to a wound a composition of any one of the previous claims.

16 . The method of claim 15 , wherein said wound is an ocular wound, and wherein the method comprises applying to said ocular wound any one composition of claims 1 - 14 .

17 . The method of any one of claims 15 - 16 , wherein said composition is in a form of an eye drop, suspension, emulsion, dispersion, or gel.

18 . The method of any one of claims 15 - 17 , wherein said composition is in a form of an eye drop, emulsion, or gel.

19 . The method of any one of claims 15 - 18 , wherein said wound is an ocular wound resulting from an ocular surgery.

20 . The method of any one of claims 15 - 19 , wherein said wound is an ocular wound resulting from cataract surgery.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2011
From: ZHANG, JINZHONG; WARD, KEITH; LOPEZ, FRANCISCO J.; JONASSE, MATTHEW
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 027219/0377 →